vs

Side-by-side financial comparison of BV Financial, Inc. (BVFL) and IRIDEX CORP (IRIX). Click either name above to swap in a different company.

IRIDEX CORP is the larger business by last-quarter revenue ($14.7M vs $10.5M, roughly 1.4× BV Financial, Inc.). On growth, BV Financial, Inc. posted the faster year-over-year revenue change (9.2% vs -69.7%). Over the past eight quarters, IRIDEX CORP's revenue compounded faster (11.9% CAGR vs 11.1%).

Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

BVFL vs IRIX — Head-to-Head

Bigger by revenue
IRIX
IRIX
1.4× larger
IRIX
$14.7M
$10.5M
BVFL
Growing faster (revenue YoY)
BVFL
BVFL
+78.9% gap
BVFL
9.2%
-69.7%
IRIX
Faster 2-yr revenue CAGR
IRIX
IRIX
Annualised
IRIX
11.9%
11.1%
BVFL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BVFL
BVFL
IRIX
IRIX
Revenue
$10.5M
$14.7M
Net Profit
$4.8M
Gross Margin
37.2%
Operating Margin
66.9%
Net Margin
45.6%
Revenue YoY
9.2%
-69.7%
Net Profit YoY
146.2%
EPS (diluted)
$0.52

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BVFL
BVFL
IRIX
IRIX
Q4 25
$10.5M
$14.7M
Q3 25
$10.0M
$12.5M
Q2 25
$9.9M
$13.6M
Q1 25
$9.2M
$11.9M
Q4 24
$9.7M
$12.7M
Q3 24
$10.0M
$11.6M
Q2 24
$9.5M
$12.6M
Q1 24
$8.5M
$11.8M
Net Profit
BVFL
BVFL
IRIX
IRIX
Q4 25
$4.8M
Q3 25
$3.7M
$-1.6M
Q2 25
$2.9M
$-994.0K
Q1 25
$2.1M
$-1.7M
Q4 24
$2.0M
$-834.0K
Q3 24
$3.8M
$-1.9M
Q2 24
$3.4M
$-2.7M
Q1 24
$2.6M
$-3.5M
Gross Margin
BVFL
BVFL
IRIX
IRIX
Q4 25
37.2%
Q3 25
32.1%
Q2 25
34.5%
Q1 25
42.5%
Q4 24
44.0%
Q3 24
37.3%
Q2 24
40.7%
Q1 24
37.9%
Operating Margin
BVFL
BVFL
IRIX
IRIX
Q4 25
66.9%
Q3 25
51.5%
-11.3%
Q2 25
39.9%
-6.9%
Q1 25
29.4%
-1.7%
Q4 24
29.5%
-3.9%
Q3 24
52.4%
-16.1%
Q2 24
49.6%
-20.9%
Q1 24
42.1%
-28.0%
Net Margin
BVFL
BVFL
IRIX
IRIX
Q4 25
45.6%
Q3 25
37.2%
-12.6%
Q2 25
29.0%
-7.3%
Q1 25
22.9%
-14.2%
Q4 24
20.2%
-6.6%
Q3 24
38.0%
-16.7%
Q2 24
35.8%
-21.2%
Q1 24
30.1%
-29.5%
EPS (diluted)
BVFL
BVFL
IRIX
IRIX
Q4 25
$0.52
Q3 25
$0.41
$-0.09
Q2 25
$0.29
$-0.06
Q1 25
$0.21
$-0.10
Q4 24
$0.18
$-0.05
Q3 24
$0.35
$-0.12
Q2 24
$0.32
$-0.16
Q1 24
$0.24
$-0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BVFL
BVFL
IRIX
IRIX
Cash + ST InvestmentsLiquidity on hand
$55.7M
$6.0M
Total DebtLower is stronger
$35.0M
Stockholders' EquityBook value
$183.8M
Total Assets
$912.2M
$29.2M
Debt / EquityLower = less leverage
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BVFL
BVFL
IRIX
IRIX
Q4 25
$55.7M
$6.0M
Q3 25
$63.5M
$5.6M
Q2 25
$56.3M
$6.8M
Q1 25
$70.8M
$7.2M
Q4 24
$70.5M
$2.4M
Q3 24
$94.1M
$3.9M
Q2 24
$90.6M
$4.1M
Q1 24
$78.8M
$5.4M
Total Debt
BVFL
BVFL
IRIX
IRIX
Q4 25
$35.0M
Q3 25
$35.0M
Q2 25
$35.0M
Q1 25
$49.9M
Q4 24
$49.9M
$1.0M
Q3 24
$34.8M
$1.4M
Q2 24
$34.8M
Q1 24
$34.8M
Stockholders' Equity
BVFL
BVFL
IRIX
IRIX
Q4 25
$183.8M
Q3 25
$190.2M
$4.7M
Q2 25
$198.0M
$6.1M
Q1 25
$198.1M
$852.0K
Q4 24
$195.5M
$2.1M
Q3 24
$209.7M
$2.6M
Q2 24
$205.5M
$4.2M
Q1 24
$201.8M
$6.5M
Total Assets
BVFL
BVFL
IRIX
IRIX
Q4 25
$912.2M
$29.2M
Q3 25
$909.4M
$28.4M
Q2 25
$908.3M
$31.6M
Q1 25
$921.9M
$34.2M
Q4 24
$911.8M
$29.1M
Q3 24
$892.7M
$30.2M
Q2 24
$897.2M
$31.2M
Q1 24
$892.5M
$34.1M
Debt / Equity
BVFL
BVFL
IRIX
IRIX
Q4 25
0.19×
Q3 25
0.18×
Q2 25
0.18×
Q1 25
0.25×
Q4 24
0.26×
0.48×
Q3 24
0.17×
0.53×
Q2 24
0.17×
Q1 24
0.17×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BVFL
BVFL
IRIX
IRIX
Operating Cash FlowLast quarter
$19.0M
Free Cash FlowOCF − Capex
$18.8M
FCF MarginFCF / Revenue
178.2%
Capex IntensityCapex / Revenue
2.2%
Cash ConversionOCF / Net Profit
3.96×
TTM Free Cash FlowTrailing 4 quarters
$34.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BVFL
BVFL
IRIX
IRIX
Q4 25
$19.0M
Q3 25
$8.4M
$-1.2M
Q2 25
$2.7M
$-397.0K
Q1 25
$4.4M
$-1.1M
Q4 24
$16.1M
$-1.2M
Q3 24
$6.1M
$-3.1M
Q2 24
$1.5M
$-1.3M
Q1 24
$4.6M
$-1.6M
Free Cash Flow
BVFL
BVFL
IRIX
IRIX
Q4 25
$18.8M
Q3 25
$8.4M
$-1.2M
Q2 25
$2.6M
$-410.0K
Q1 25
$4.2M
$-1.2M
Q4 24
$15.5M
$-1.2M
Q3 24
$6.0M
$-3.1M
Q2 24
$1.4M
Q1 24
$4.1M
$-1.7M
FCF Margin
BVFL
BVFL
IRIX
IRIX
Q4 25
178.2%
Q3 25
84.0%
-9.4%
Q2 25
26.1%
-3.0%
Q1 25
46.0%
-9.8%
Q4 24
160.0%
-9.8%
Q3 24
59.6%
-26.5%
Q2 24
15.2%
Q1 24
48.4%
-14.0%
Capex Intensity
BVFL
BVFL
IRIX
IRIX
Q4 25
2.2%
Q3 25
0.1%
0.1%
Q2 25
1.4%
0.1%
Q1 25
2.4%
0.1%
Q4 24
6.3%
0.1%
Q3 24
1.0%
0.0%
Q2 24
0.6%
0.0%
Q1 24
5.1%
0.0%
Cash Conversion
BVFL
BVFL
IRIX
IRIX
Q4 25
3.96×
Q3 25
2.26×
Q2 25
0.95×
Q1 25
2.11×
Q4 24
8.23×
Q3 24
1.60×
Q2 24
0.44×
Q1 24
1.77×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons